| Robert A Cure, MD | |
|
2855 Campus Dr, Suite 400, Plymouth, MN 55441-2659 | |
| (612) 577-7400 | |
| Not Available |
| Full Name | Robert A Cure |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 41 Years |
| Location | 2855 Campus Dr, Plymouth, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346203981 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 28914 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abbott Northwestern Hospital | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm's proprietary Ligand Activated Therapy (LAT) prodrug approach.
A day after President Donald Trump said the Affordable Care Act "has been repealed," officials reported that 8.8 million Americans have signed up for coverage on the federal insurance exchange in 2018 — nearly reaching 2017's number in half the sign-up time.
Salvation Army Emergency and Disaster Services staff were on hand for the second time this week to welcome Haitian evacuees and children bound for adoption by Canadian families upon their arrival at Ottawa International Airport.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs.
Silvia Mamede, M.D., Ph.D., of Erasmus University Rotterdam, the Netherlands and colleagues investigated whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias.
› Verified 7 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm's proprietary Ligand Activated Therapy (LAT) prodrug approach.
A day after President Donald Trump said the Affordable Care Act "has been repealed," officials reported that 8.8 million Americans have signed up for coverage on the federal insurance exchange in 2018 — nearly reaching 2017's number in half the sign-up time.
Salvation Army Emergency and Disaster Services staff were on hand for the second time this week to welcome Haitian evacuees and children bound for adoption by Canadian families upon their arrival at Ottawa International Airport.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs.
Silvia Mamede, M.D., Ph.D., of Erasmus University Rotterdam, the Netherlands and colleagues investigated whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias.
› Verified 7 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm's proprietary Ligand Activated Therapy (LAT) prodrug approach.
A day after President Donald Trump said the Affordable Care Act "has been repealed," officials reported that 8.8 million Americans have signed up for coverage on the federal insurance exchange in 2018 — nearly reaching 2017's number in half the sign-up time.
Salvation Army Emergency and Disaster Services staff were on hand for the second time this week to welcome Haitian evacuees and children bound for adoption by Canadian families upon their arrival at Ottawa International Airport.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs.
Silvia Mamede, M.D., Ph.D., of Erasmus University Rotterdam, the Netherlands and colleagues investigated whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert A Cure, MD 2925 Chicago Ave, Minneapolis, MN 55407-1321 Ph: (612) 262-5000 | Robert A Cure, MD 2855 Campus Dr, Suite 400, Plymouth, MN 55441-2659 Ph: (612) 577-7400 |
News Archive
KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm's proprietary Ligand Activated Therapy (LAT) prodrug approach.
A day after President Donald Trump said the Affordable Care Act "has been repealed," officials reported that 8.8 million Americans have signed up for coverage on the federal insurance exchange in 2018 — nearly reaching 2017's number in half the sign-up time.
Salvation Army Emergency and Disaster Services staff were on hand for the second time this week to welcome Haitian evacuees and children bound for adoption by Canadian families upon their arrival at Ottawa International Airport.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs.
Silvia Mamede, M.D., Ph.D., of Erasmus University Rotterdam, the Netherlands and colleagues investigated whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias.
› Verified 7 days ago
Melanie A Hoiland, PA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1495 Hwy 101 N, Plymouth, MN 55447 Phone: 763-476-6776 | |
Eric Michael Thompson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2805 Campus Dr Ste 115, Plymouth, MN 55441 Phone: 763-577-7800 Fax: 763-577-7855 | |
Dr. Shelly L Anderson, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1495 Hwy 101 North, Plymouth, MN 55447 Phone: 763-476-6776 | |
Mr. Mancel Talcott Mitchell Iii, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15655 37th Ave N Ste 100, Plymouth, MN 55446 Phone: 763-587-7900 Fax: 763-587-7701 | |
Lawrence Gale Richmond, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4155 County Road 101 N, Plymouth, MN 55446 Phone: 952-993-8900 | |
Christine S Chang, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12805 Highway 55, Suite 111, Plymouth, MN 55441 Phone: 763-577-2060 Fax: 763-577-2099 | |
David S. Johnson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2855 Campus Dr, Suite 400, Plymouth, MN 55441 Phone: 763-577-7400 |